$KPTI News

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...

Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to $3

Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move

Why Is KPTI Stock Down 69% After-Hours Today?

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Karyopharm Therapeutics Announces Topline Results From Its Phase 3 XPORT-EC-042 Trial Evaluating Selinexor In Adult Patients With TP53 Wild-Type Advanced Or Recurrent Endometrial Cancer; Trial Did Not Meet Its Primary Endpoint Of Progression Free Survival

Karyopharm Therapeutics To Submit FDA Supplemental New Drug Application In August 2026 For Accelerated Approval Of Selinexor In Combination With Ruxolitinib To Treat Myelofibrosis

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?